Physician profile
Jonathan S Crane
NPI 1134187594
$14,182.97
in general payments reported to CMS, 2019-2025
33 companies · $4,220 in 2025
The $4,220 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642 · 2020: $446 · 2021: $781 · 2022: $1,863 · 2023: $2,467 · 2024: $3,764 · 2025: $4,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,946 · Education: $504.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,945.97 |
| Education | $504.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,085.63 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,447.81 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $1,284.37 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $1,128.85 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $859.52 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $695.51 | 2019-2025 | Libtayo, Dupixent |
| Pfizer INC. | $671.78 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $664.09 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $528.83 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $493.21 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $440.12 | 2019-2025 | Adbry |
| Lilly USA, LLC | $381.70 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $355.58 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $327.22 | 2019-2025 | Aklief, Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $317.11 | 2020-2025 | Cabtreo, Siliq, Jublia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $304.37 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $268.79 | 2022-2025 | Tremfya |
| Organon LLC | $234.32 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.13 | 2023-2025 | Spevigo, Cyltezo |
| Convatec INC. | $137.19 | 2024 | |
| Organogenesis INC. | $76.65 | 2021-2025 | Affinity, Puraply Wound Matrix |
| Genentech USA, INC. | $46.10 | 2019-2023 | Xolair |
| Amgen INC. | $41.06 | 2023-2025 | Otezla, Otezla |
| Biofrontera INC. | $31.97 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $31.45 | 2020-2021 | |
| Almirall LLC | $21.37 | 2021 | |
| Celgene Corporation | $20.51 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.91 | 2019 | |
| Epi Health, LLC | $15.03 | 2020 | |
| Verrica Pharmaceuticals INC. | $14.92 | 2025 | Ycanth |
| Aclaris Therapeutics, INC. | $13.54 | 2019 | |
| Allergan, INC. | $12.39 | 2019 | |
| Kerecis Limited | $9.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.